And in many cases standard treatments with Lupron (leuprolide) or Zoladex (goserelin) is commonly not readily available and/or too highly-priced. Just lately developed ADT treatments like abiraterone and enzalutamide are solely out of access fiscally for some African patients and infrequently not out there at all in very low- and reduce-middle-cash